Newly-discovered and future biomarkers are likely to help oncologists give an accurate prognosis and to prescribe more effective treatment for patients with multiple myeloma.
Study "opens the possibility" to "convert partial responses into real cures."
CTA interviewed Dr Sarah Vinnicombe about her recent article on the role of breast MRI for breast cancer staging and screening.
Despite widespread stigma and efforts to limit prevalence, ghost and honorary authorship remain widespread in clinical trials.
Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it's unclear the role it will have in the first-line.
Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.
A newly released survey of clinical testing finds that widely divergent methodologies for MRD testing remain a continuing challenge.
Speakers at the 2016 Concordia Summit's panel, "Precision Medicine in Cancer Research," discussed the importance and future of immunotherapy for cancer treatment.
In this question-and-answer session, CTA asked Dr Carroll about CRISPR-Cas9, the state of the science of genome editing, and its implications for oncology.
Researchers are attempting to determine the usefulness of mindfulness for cancer pain.
CRISPR is receiving attention as a gene-editing tool that may help us treat cancer, but evolutionary theory suggests a much more complex reality.
Overselling scientific data contributes to misunderstanding, failure, and disappointment in real-world settings.
Many studies show that EUS has a significant benefit over risk ratio, although more data is needed to fully understand the potential of EUS in screening for pancreatic cancer.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC).
Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?
While immune checkpoint inhibitors show real promise for treating lung cancer, better predictive biomarkers are necessary to make the therapy more effective.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Statins Linked to Improved Overall Survival in Multiple Myeloma
- Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
- Ghost and Honorary Authorship in Cancer Research
- Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
- Minimal Residual Disease and Treatment Response in Multiple Myeloma
- PSA Testing Unchanged in Years After USPSTF Recommendation
- Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
- MRI May Be Effective Screening Test for Hepatocellular Carcinoma
- Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP
- Emerging Prognostic Markers Continue to Improve Myeloma Treatment